Return to main menu Help

BETAXOLOL [EYE]

Names
Common NameBETAXOLOL [EYE]
Other NameBETAXOLOL [EYE]
Pharmacological GroupCARDIOSELECTIVE BETA BLOCKERS
Chemical Name1-{4-[2-(Cyclopropylmethoxy)ethyl]phenoxy}-3-isopropylaminopropan-2-ol hydrochloride
Chemical Group

Attributes

IndicationsContraindicationsPrescriber CautionsPatient Cautions
ToxicitySide EffectsLiver DiseaseRenal Failure
PregnancyLactationPharmacological ActionsDiagnostic Procedures
DrugsInteractions

Indications

Glaucoma
Open-angle glaucoma

Contraindications

Heart failure
Chronic obstructive airway disease
Asthma
Pulse rate - bradycardia
Complete atrioventricular block
Partial atrioventricular block
Sick sinus syndrome
Raynaud's syndrome
Chronic obstructive pulmonary disease
Chronic asthmatic bronchitis
Cardiogenic shock
Adverse reaction to betablockers
Airways obstruction reversible
Beta blocker contraindicated
Betablocker allergy

Prescriber Cautions

Caution in asthma or other obstructive pulmonary disease

Patient Cautions

See information on products containing BETAXOLOL [EYE] for specific advice for patients

Toxicity

- None Listed -

Side Effects

Anti-nuclear factor positive - Rare
Asthma - Rare
Bradycardia - Rare
Bronchospasm - Rare
Cardiac conduction disorders - Rare
Cold extremities - Rare
Confusion - Rare
Depression - Rare
Diarrhoea - Rare
Dizziness - Rare
Drug psychoses - Rare
Dry eyes - Rare
Dyspnoea - Rare
Fatigue/asthenia - Rare
Hallucinations - Rare
Headache - Rare
Heart failure - Rare
Hypotension - Rare
Impotence - Rare
Insomnia - Rare
Intermittent claudication - Rare
Nausea - Rare
Nightmares - Rare
Paraesthesia - Rare
Patches of alopecia - Rare
Rash - Rare
Raynaud's phenomenon - Rare
Visual symptoms - Rare
Vomiting - Rare
Anisocoria
Erythema
Itching
Keratitis
Photophobia
Watering eyes

Liver Disease

Liver disease may alter the response to drugs in several ways. Prescribing should be kept to a minimum in all patients with severe liver disease, especially if jaundice, ascites, or evidence of encephalopathy present

Renal Failure

BETAXOLOL [EYE] - may reduce renal blood flow and reduce renal function in severe renal failure

Pregnancy

BETAXOLOL [EYE] may retard intrauterine fetal growth
BETAXOLOL [EYE] causes neonatal bradycardia related to maternal dose
Avoid BETAXOLOL [EYE] in the 1st & 2nd TRIMESTER of pregnancy
Risk of neonatal hypoglycaemia with BETAXOLOL [EYE]

Lactation

Therapeutic doses of BETAXOLOL [EYE] unlikely to affect infant
BETAXOLOL [EYE] unlikely to be excreted in milk
Monitor infant
Possible toxicity from BETAXOLOL [EYE] due to beta-blocker effect

Pharmacological Actions

BETA ANTAGONIST action effect
BETA1 ANTAGONIST effect

Diagnostic Procedures

Urine 5-hydroxyindoleacetic acid high
Total bilirubin high
Creatine kinase low
Serum glucose low

Drugs containing BETAXOLOL [EYE]

BETOPTIC 0.5% eye drops 5mL
BETAXOLOL 0.25% eye drops
BETOPTIC SUSPENS 0.25% e/d 5mL
BETOPTIC 0.25% s-d eye 0.25mL
BETAXOLOL 0.25% s-d eye drops
BETAXOLOL 0.5% eye drops

Interacting Ingredients

ACETOHEXAMIDE
Infrequent reports of BETAXOLOL [EYE] increasing the HYPOGLYCAEMIC effect of ACETOHEXAMIDE. Moderate risk. Monitor
ALFUZOSIN HYDROCHLORIDE
Infrequent reports of BETAXOLOL [EYE] increasing the HYPOTENSIVE effect of ALFUZOSIN HYDROCHLORIDE. Potential risk. May need to avoid combination
ALMOTRIPTAN
Infrequent reports of BETAXOLOL [EYE] increasing the VASOCONSTRICTOR effect of ALMOTRIPTAN. Potential risk. Avoid
AMINOPHYLLINE
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of AMINOPHYLLINE. Potential risk. Avoid
BAMBUTEROL HYDROCHLORIDE
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of BAMBUTEROL HYDROCHLORIDE. Potential risk. Avoid
BECLOMETASONE [INHALED]
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of BECLOMETASONE [INHALED]. Potential risk. Avoid
BETAMETHASONE [INHALED]
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of BETAMETHASONE [INHALED]. Potential risk. Avoid
BIPHASIC INSULIN ASPART
Infrequent reports of BETAXOLOL [EYE] increasing the HYPOGLYCAEMIC effect of BIPHASIC INSULIN ASPART. Moderate risk. Monitor
BIPHASIC INSULIN LISPRO
Infrequent reports of BETAXOLOL [EYE] increasing the HYPOGLYCAEMIC effect of BIPHASIC INSULIN LISPRO. Moderate risk. Monitor
BUDESONIDE [INHALED]
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of BUDESONIDE [INHALED]. Potential risk. Avoid
BUFYLLINE
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of BUFYLLINE. Potential risk. Avoid
CHLORPROPAMIDE
Infrequent reports of BETAXOLOL [EYE] increasing the HYPOGLYCAEMIC effect of CHLORPROPAMIDE. Moderate risk. Monitor
CHOLINE THEOPHYLLINATE
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of CHOLINE THEOPHYLLINATE. Potential risk. Avoid
CLONIDINE
Likely interaction of BETAXOLOL [EYE] increasing the HYPOTENSIVE effect of CLONIDINE. Potential risk. May need to avoid combination
CROMOGLICATE [INHALED]
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of CROMOGLICATE [INHALED]. Potential risk. Avoid
DARBEPOETIN ALFA
Theoretical potential for DARBEPOETIN ALFA reducing the HYPOTENSIVE effect of BETAXOLOL [EYE]. Moderate risk. Monitor
DIGITOXIN
Infrequent reports of BETAXOLOL [EYE] increasing the NEGATIVE CHRONOTROPIC effect of DIGITOXIN. Moderate risk. May need to avoid combination
DIGOXIN
Infrequent reports of BETAXOLOL [EYE] increasing the NEGATIVE CHRONOTROPIC effect of DIGOXIN. Moderate risk. May need to avoid combination
DIHYDROERGOTAMINE MESILATE
Infrequent reports of DIHYDROERGOTAMINE MESILATE increasing the VASOCONSTRICTOR effect of BETAXOLOL [EYE]. Moderate risk. Monitor
DILTIAZEM HYDROCHLORIDE
Infrequent reports of DILTIAZEM HYDROCHLORIDE increasing the NEGATIVE INOTROPIC effect of BETAXOLOL [EYE]. Moderate risk. Monitor
DIPROPHYLLINE
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of DIPROPHYLLINE. Potential risk. Avoid
DISOPYRAMIDE
Infrequent reports of BETAXOLOL [EYE] increasing the NEGATIVE CHRONOTROPIC effect of DISOPYRAMIDE. Moderate risk. May need to avoid combination
DISTIGMINE
Infrequent reports of DISTIGMINE increasing the NEGATIVE CHRONOTROPIC effect of BETAXOLOL [EYE]. Moderate risk. Monitor
EDROPHONIUM
Infrequent reports of EDROPHONIUM increasing the NEGATIVE CHRONOTROPIC effect of BETAXOLOL [EYE]. Moderate risk. Monitor
ELETRIPTAN
Infrequent reports of BETAXOLOL [EYE] increasing the VASOCONSTRICTOR effect of ELETRIPTAN. Potential risk. Avoid
EPHEDRINE HYDROCHLORIDE
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of EPHEDRINE HYDROCHLORIDE. Potential risk. Avoid
EPOETIN ALFA
Theoretical potential for EPOETIN ALFA reducing the HYPOTENSIVE effect of BETAXOLOL [EYE]. Moderate risk. Monitor
EPOETIN BETA
Theoretical potential for EPOETIN BETA reducing the HYPOTENSIVE effect of BETAXOLOL [EYE]. Moderate risk. Monitor
EPOETIN THETA
Theoretical potential for EPOETIN THETA reducing the HYPOTENSIVE effect of BETAXOLOL [EYE]. Moderate risk. Monitor
EPOETIN ZETA
Theoretical potential for EPOETIN ZETA reducing the HYPOTENSIVE effect of BETAXOLOL [EYE]. Moderate risk. Monitor
ERGOTAMINE TARTRATE
Infrequent reports of ERGOTAMINE TARTRATE increasing the VASOCONSTRICTOR effect of BETAXOLOL [EYE]. Moderate risk. Monitor
FELODIPINE
Infrequent reports of FELODIPINE increasing the NEGATIVE INOTROPIC effect of BETAXOLOL [EYE]. Moderate risk. Monitor
FENOTEROL HYDROBROMIDE
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of FENOTEROL HYDROBROMIDE. Potential risk. Avoid
FLECAINIDE ACETATE
Infrequent reports of BETAXOLOL [EYE] increasing the BETA ANTAGONIST effect of FLECAINIDE ACETATE. Moderate risk. Monitor
FLUTICASONE [INHALED]
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of FLUTICASONE [INHALED]. Potential risk. Avoid
FORMOTEROL
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of FORMOTEROL. Potential risk. Avoid
FROVATRIPTAN
Infrequent reports of BETAXOLOL [EYE] increasing the VASOCONSTRICTOR effect of FROVATRIPTAN. Potential risk. Avoid
GALANTAMINE
Infrequent reports of GALANTAMINE increasing the NEGATIVE CHRONOTROPIC effect of BETAXOLOL [EYE]. Moderate risk. Monitor
GLIBENCLAMIDE
Infrequent reports of BETAXOLOL [EYE] increasing the HYPOGLYCAEMIC effect of GLIBENCLAMIDE. Moderate risk. Monitor
GLIBORNURIDE
Infrequent reports of BETAXOLOL [EYE] increasing the HYPOGLYCAEMIC effect of GLIBORNURIDE. Moderate risk. Monitor
GLICLAZIDE
Infrequent reports of BETAXOLOL [EYE] increasing the HYPOGLYCAEMIC effect of GLICLAZIDE. Moderate risk. Monitor
GLIMEPIRIDE
Infrequent reports of BETAXOLOL [EYE] increasing the HYPOGLYCAEMIC effect of GLIMEPIRIDE. Moderate risk. Monitor
GLIPIZIDE
Infrequent reports of BETAXOLOL [EYE] increasing the HYPOGLYCAEMIC effect of GLIPIZIDE. Moderate risk. Monitor
GLIQUIDONE
Infrequent reports of BETAXOLOL [EYE] increasing the HYPOGLYCAEMIC effect of GLIQUIDONE. Moderate risk. Monitor
GLYMIDINE
Infrequent reports of BETAXOLOL [EYE] increasing the HYPOGLYCAEMIC effect of GLYMIDINE. Moderate risk. Monitor
HUMAN INSULIN [INHALED]
Infrequent reports of BETAXOLOL [EYE] increasing the HYPOGLYCAEMIC effect of HUMAN INSULIN [INHALED]. Moderate risk. Monitor
INDACATEROL
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of INDACATEROL. Potential risk. Avoid
INSULIN ASPART
Infrequent reports of BETAXOLOL [EYE] increasing the HYPOGLYCAEMIC effect of INSULIN ASPART. Moderate risk. Monitor
INSULIN DETEMIR
Infrequent reports of BETAXOLOL [EYE] increasing the HYPOGLYCAEMIC effect of INSULIN DETEMIR. Moderate risk. Monitor
INSULIN GLARGINE
Infrequent reports of BETAXOLOL [EYE] increasing the HYPOGLYCAEMIC effect of INSULIN GLARGINE. Moderate risk. Monitor
INSULIN GLULISINE
Infrequent reports of BETAXOLOL [EYE] increasing the HYPOGLYCAEMIC effect of INSULIN GLULISINE. Moderate risk. Monitor
INSULIN LISPRO
Infrequent reports of BETAXOLOL [EYE] increasing the HYPOGLYCAEMIC effect of INSULIN LISPRO. Moderate risk. Monitor
ISOETARINE HYDROCHLORIDE
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of ISOETARINE HYDROCHLORIDE. Potential risk. Avoid
ISOPRENALINE HYDROCHLORIDE
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of ISOPRENALINE HYDROCHLORIDE. Potential risk. Avoid
ISOPRENALINE SULPHATE
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of ISOPRENALINE SULPHATE. Potential risk. Avoid
ISRADIPINE
Infrequent reports of ISRADIPINE increasing the NEGATIVE INOTROPIC effect of BETAXOLOL [EYE]. Moderate risk. Monitor
KETOTIFEN
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of KETOTIFEN. Potential risk. Avoid
LACIDIPINE
Infrequent reports of LACIDIPINE increasing the NEGATIVE INOTROPIC effect of BETAXOLOL [EYE]. Moderate risk. Monitor
LERCANIDIPINE
Infrequent reports of LERCANIDIPINE increasing the NEGATIVE INOTROPIC effect of BETAXOLOL [EYE]. Moderate risk. Monitor
MEFLOQUINE HYDROCHLORIDE
Likely interaction of BETAXOLOL [EYE] increasing the ARRHYTHMOGENIC effect of MEFLOQUINE HYDROCHLORIDE. Moderate risk. May need to avoid combination
METFORMIN HYDROCHLORIDE
Infrequent reports of BETAXOLOL [EYE] increasing the HYPOGLYCAEMIC effect of METFORMIN HYDROCHLORIDE. Moderate risk. Monitor
METHOXY POLYETHYLENE GLYCOL EPOETIN BETA
Theoretical potential for METHOXY POLYETHYLENE GLYCOL EPOETIN BETA reducing the HYPOTENSIVE effect of BETAXOLOL [EYE]. Moderate risk. Monitor
METHYSERGIDE
Infrequent reports of METHYSERGIDE increasing the VASOCONSTRICTOR effect of BETAXOLOL [EYE]. Moderate risk. Monitor
MONTELUKAST
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of MONTELUKAST. Potential risk. Avoid
MOXISYLYTE
Likely interaction of BETAXOLOL [EYE] increasing the HYPOTENSIVE effect of MOXISYLYTE. Potential risk. May need to avoid combination
NEDOCROMIL SODIUM
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of NEDOCROMIL SODIUM. Potential risk. Avoid
NEOSTIGMINE
Infrequent reports of NEOSTIGMINE increasing the NEGATIVE CHRONOTROPIC effect of BETAXOLOL [EYE]. Moderate risk. Monitor
NICARDIPINE HYDROCHLORIDE
Infrequent reports of NICARDIPINE HYDROCHLORIDE increasing the NEGATIVE INOTROPIC effect of BETAXOLOL [EYE]. Moderate risk. Monitor
NIFEDIPINE
Infrequent reports of NIFEDIPINE increasing the NEGATIVE INOTROPIC effect of BETAXOLOL [EYE]. Moderate risk. Monitor
NIMODIPINE
Infrequent reports of NIMODIPINE increasing the NEGATIVE INOTROPIC effect of BETAXOLOL [EYE]. Moderate risk. Monitor
NISOLDIPINE
Infrequent reports of NISOLDIPINE increasing the NEGATIVE INOTROPIC effect of BETAXOLOL [EYE]. Moderate risk. Monitor
ORCIPRENALINE
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of ORCIPRENALINE. Potential risk. Avoid
ORCIPRENALINE [INHALED]
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of ORCIPRENALINE [INHALED]. Potential risk. Avoid
PIRBUTEROL
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of PIRBUTEROL. Potential risk. Avoid
PIROXICAM
Likely interaction of PIROXICAM reducing the HYPOTENSIVE effect of BETAXOLOL [EYE]. Moderate risk. Monitor
PIROXICAM [RECTUM]
Likely interaction of PIROXICAM [RECTUM] reducing the HYPOTENSIVE effect of BETAXOLOL [EYE]. Moderate risk. Monitor
PIROXICAM-BETADEX
Likely interaction of PIROXICAM-BETADEX reducing the HYPOTENSIVE effect of BETAXOLOL [EYE]. Moderate risk. Monitor
PRAZOSIN HYDROCHLORIDE
Infrequent reports of BETAXOLOL [EYE] increasing the HYPOTENSIVE effect of PRAZOSIN HYDROCHLORIDE. Potential risk. May need to avoid combination
PRENYLAMINE
Likely interaction of BETAXOLOL [EYE] increasing the NEGATIVE INOTROPIC effect of PRENYLAMINE. High risk. Monitor
PYRIDOSTIGMINE BROMIDE
Infrequent reports of PYRIDOSTIGMINE BROMIDE increasing the NEGATIVE CHRONOTROPIC effect of BETAXOLOL [EYE]. Moderate risk. Monitor
QUINIDINE
Infrequent reports of BETAXOLOL [EYE] increasing the NEGATIVE CHRONOTROPIC effect of QUINIDINE. Moderate risk. May need to avoid combination
REPROTEROL HYDROCHLORIDE
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of REPROTEROL HYDROCHLORIDE. Potential risk. Avoid
RIMITEROL HYDROBROMIDE
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of RIMITEROL HYDROBROMIDE. Potential risk. Avoid
RITODRINE HYDROCHLORIDE
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of RITODRINE HYDROCHLORIDE. Potential risk. Avoid
SALBUTAMOL
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of SALBUTAMOL. Potential risk. Avoid
SALBUTAMOL [INHALED]
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of SALBUTAMOL [INHALED]. Potential risk. Avoid
SALMETEROL XINAFOATE
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of SALMETEROL XINAFOATE. Potential risk. Avoid
SUMATRIPTAN SUCCINATE
Infrequent reports of BETAXOLOL [EYE] increasing the VASOCONSTRICTOR effect of SUMATRIPTAN SUCCINATE. Potential risk. Avoid
TERAZOSIN HYDROCHLORIDE
Infrequent reports of BETAXOLOL [EYE] increasing the HYPOTENSIVE effect of TERAZOSIN HYDROCHLORIDE. Potential risk. May need to avoid combination
TERBUTALINE
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of TERBUTALINE. Potential risk. Avoid
TERBUTALINE [INHALED]
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of TERBUTALINE [INHALED]. Potential risk. Avoid
THEOPHYLLINE
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of THEOPHYLLINE. Potential risk. Avoid
TOLAZAMIDE
Infrequent reports of BETAXOLOL [EYE] increasing the HYPOGLYCAEMIC effect of TOLAZAMIDE. Moderate risk. Monitor
TOLBUTAMIDE
Infrequent reports of BETAXOLOL [EYE] increasing the HYPOGLYCAEMIC effect of TOLBUTAMIDE. Moderate risk. Monitor
TULOBUTEROL HYDROCHLORIDE
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of TULOBUTEROL HYDROCHLORIDE. Potential risk. Avoid
VERAPAMIL HYDROCHLORIDE
Infrequent reports of VERAPAMIL HYDROCHLORIDE increasing the NEGATIVE INOTROPIC effect of BETAXOLOL [EYE]. Moderate risk. Monitor
ZAFIRLUKAST
Infrequent reports of BETAXOLOL [EYE] reducing the BRONCHODILATOR effect of ZAFIRLUKAST. Potential risk. Avoid
Copyright © SafeScript Ltd. / Fern Information Systems Ltd. 2001